Monday, April 20, 2026

#Outdoor roaming of owned #cats elevates #risk of zoonotic #pathogen #exposure: A global synthesis

 


Abstract

Domestic animals play a central role in pathogen transmission at the human–wildlife interface. Domestic cats, in particular, are uniquely consequential in disease spillover dynamics due to their global distribution, large, human-subsidized free-roaming populations, and high contact rate with humans, domestic animals, and wildlife. However, the extent to which human ownership and management mitigate this spillover risk remains a key knowledge gap. To address this gap, we conducted a global systematic review and quantitative synthesis of the prevalence and diversity of zoonotic pathogens in indoor-only, outdoor-owned (roaming unsupervised), and unowned (feral or stray) cats. Our dataset comprised 174,064 individuals from 88 countries, representing 124 pathogen species, 97 of which are zoonotic. Using generalized linear models within a Bayesian framework and rarefaction analyses, we show that ownership provides limited protection against zoonoses when owned cats have unsupervised outdoor access. Outdoor-owned cats were 3–5 times more likely to carry zoonotic pathogens than indoor-only cats, and, notably, had infection odds statistically equivalent to those of feral cats, despite receiving presumed veterinary care and feeding. Feral cats carried the highest pathogen diversity, however, outdoor-owned cats still harbour 1.5 times the helminth richness of indoor cats, highlighting their potential as effective bridges for pathogen spillover. With approximately 62% of owned cats roaming freely worldwide, and rates exceeding 90% in some regions, these findings reveal a major yet overlooked route of zoonotic risk. Public health and One Health frameworks have traditionally focused on feral cats; however, our results highlight the need to explicitly incorporate owned outdoor cats into zoonotic disease prevention strategies by restricting unsupervised roaming and promoting responsible ownership practices. Without such integration, current frameworks risk overlooking a pervasive and preventable pathway for pathogen transmission at the human–wildlife–domestic animal interface.

Source: 


Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014160

____

#Surveillance and #control efficacy of the Bergerac, #France, 2025 #chikungunya #outbreak

 


Abstract

The spread of the highly invasive mosquito, Aedes albopictus, across Europe, combined with climate change and human travel and trade, has led to new epidemic threats from mosquito-borne viruses, most significantly dengue and chikungunya, which are increasing in frequency and magnitude. In 2025, mainland France has seen a record number of autochthonous cases and outbreaks of chikungunya, spread across multiple locations, primarily introduced by travellers from the French Overseas Territory of La Réunion which is experiencing severe chikungunya outbreaks. Here, we describe one of the largest French outbreaks and subsequent control measures in the city of Bergerac, Dordogne, which resulted in 102 cases as of 5th November 2025. We apply a climate-driven mathematical model for Ae. albopictus and chikungunya virus transmission to the Bergerac 2025 outbreaks, comparing outputs to case data. The model suggests that the initial control measures in the first four weeks after the discovery of the outbreak, limited in their intervention radius and intensity, had little effect on reducing the number of cases, given the high incidence and the wide geographic extent of viral circulation. However, subsequent more widespread and intense control efforts, combined with likely increased public awareness, substantially reduced case numbers. These findings underscore the need to tailor control measures to intensity and scale of viral circulation combined with effective preventive and proactive arbovirus surveillance. Adulticides combined with public awareness campaigns can be effective for public health protection and are an important part of mitigating against the risk of Aedes-borne arboviruses and the ongoing outbreaks in mainland France.

Source: 


Link: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0014184

____

Uncomplicated #malaria as a #risk factor for #COVID19 duration and severity in western #Kenya and #Burkina Faso (MALCOV): a prospective cohort study

 


Summary

Background

The relationship between malaria and COVID-19 varies across different clinical scenarios; historical malaria exposure might protect against severe COVID-19, whereas co-infection in hospitalised patients with severe disease might increase mortality. Interactions between non-severe malaria and COVID-19 remain poorly understood. We conducted a cohort study among COVID-19 patients of all ages in western Kenya and Burkina Faso to assess the effects of acute, uncomplicated Plasmodium falciparum malaria co-infection on COVID-19 outcomes in ambulatory patients.

Methods

Participants with laboratory-confirmed SARS-CoV-2 infection (positive rapid antigen test or reverse transcription quantitative real-time PCR [RT-qPCR]) were tested for malaria by rapid antigen tests with confirmatory microscopy. Patients with COVID-19 and malaria co-infection received artemether–lumefantrine or pyronaridine–artesunate. COVID-19 symptom course was assessed daily using FLU-PRO Plus (a validated patient-reported outcome instrument) until day 14. Viral load was measured by RT-qPCR on days 0, 3, 7, 14, and 28. The primary endpoint was time to symptom resolution on the FLU-PRO Plus. Analyses were adjusted for country, age, disease severity, and viral load.

Findings

Between Jan 8, 2021 and Jan 24, 2022, we screened 5161 participants and recruited 756 with COVID-19. 742 participants with valid malaria tests were enrolled, of which 151 (20%) had malaria co-infection and the remaining 591 (80%) did not have malaria. Patients with malaria were younger (49 [32%] aged <15 years) than those without malaria (35 [6%]; p<0·0001). Time to symptom resolution was similar between those with malaria (median 9 days [IQR 5–13]) and those without (10 days [IQR 6–13]; adjusted hazard ratio [aHR] 1·14 [95% CI 0·91–1·42]; p=0·26). Three (2%) patients with malaria and nine (2%) without malaria were hospitalised; two (1%) with malaria and three (1%) without malaria died, four from acute respiratory distress syndrome and one (in the no malaria group) from perforated peptic ulcer complicated by anaemia. Participants with malaria more frequently reported moderate-to-severe symptoms at enrolment (68% vs 60%; p=0·074), but overall symptom duration was similar (adjusted incidence rate ratio 0·95 [95% CI 0·86–1·05]; p=0·31). Previous malaria exposure significantly modified outcomes, with patients with malaria co-infection and previous exposure having faster symptom clearance than those without previous exposure (pinteraction=0·042). SARS-CoV-2 clearance was slower in the malaria group by day 7 (aHR 0·69 [95% CI 0·51–0·94]; p=0·017) but was similar between groups by day 28 (adjusted risk ratio 0·99 [95% CI 0·79–1·24]; p=0·95).

Interpretation

This study shows that acute uncomplicated malaria co-infection does not adversely affect COVID-19 progression when appropriately treated. Moreover, serological evidence confirms that previous lifelong malaria exposure might provide some protection, with exposed individuals having faster symptom resolution.

Funding

Gates Foundation.

Translation

For the French translation of the abstract see Supplementary Materials section.

Source: 


Link: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00541-8/fulltext

____

A natural five-amino-acid insert at the S2’ #cleavage site of #MERS-CoV #spike enhances viral membrane fusion

 


Highlights

• A novel 5-aa insert, TSGVF, is present at the S2’ cleavage site of the spike protein of MERS-CoV from dromedary camels.

• Pseudovirus-based entry assays showed that the TSGVF insert increases viral entry efficiency in different human cells.

• Pseudovirus with TSGVF insert at the S2’ cleavage site showed strong resistance to TMPRSS2 inhibitor.

• The natural occurrence of TSGVF insert at the spike S2’ cleavage site enhances viral membrane fusion and syncytia formation.

Source: 


Link: https://www.sciencedirect.com/science/article/pii/S1995820X26000611?via%3Dihub

____

Sunday, April 19, 2026

View from the Dunes with Beach and Piers, Piet Mondrian (1909)

 


Public Domain.

Source: 


Link: https://www.wikiart.org/en/piet-mondrian/view-from-the-dunes-with-beach-and-piers-1909

____

#Coronavirus Disease Research #References (by AMEDEO, April 19 '26)

 


    Ann Intern Med

  1. ALBALOUL H, Nemer A, Saini N, Schuster MG, et al
    Infectious Diseases: What You May Have Missed in 2025.
    Ann Intern Med. 2026 Apr 14:e2600983. doi: 10.7326/ANNALS-26-00983.
    PubMed         Abstract available


    BMJ

  2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
    Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
    BMJ. 2026;393:e087578.
    PubMed         Abstract available

  3. PAGEL C
    The UK Covid-19 Inquiry lays bare the cost of delayed action for NHS staff.
    BMJ. 2026;393:s696.
    PubMed        


    Clin Infect Dis

  4. THORPE A, Lee RA, Szymczak JE, Farrell MC, et al
    Comparing the Antimicrobial Resistance Crisis to the Coronavirus Disease 2019 Pandemic: A Randomized Public Health Messaging Experiment.
    Clin Infect Dis. 2026 Apr 8:ciag110. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  5. ISMAIL H, Perovic O, Mpembe R, Lowman W, et al
    Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.
    Emerg Infect Dis. 2026;32:563-572.
    PubMed         Abstract available

  6. ANDRES C, Prats-Mendez I, Midgley S, Berginc N, et al
    Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024.
    Emerg Infect Dis. 2026;32:491-499.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  7. DUROCHER F, Dufresne SF, Dufresne PJ, Marchand-Senecal X, et al
    Healthcare-associated Pneumocystis jirovecii transmission in the era of universal masking and distancing.
    Infect Control Hosp Epidemiol. 2026 Apr 13:1-6. doi: 10.1017/ice.2026.10446.
    PubMed         Abstract available


    Int J Infect Dis

  8. NGIAM JN, Yap AJ, Wee LE, Koh MCY, et al
    Parental Vaccination Status and Other Socioeconomic Determinants Shaping COVID-19 Vaccine Uptake in Children and Adolescents in Singapore.
    Int J Infect Dis. 2026 Apr 15:108686. doi: 10.1016/j.ijid.2026.108686.
    PubMed         Abstract available

  9. ALI AS, Vanoli E, Smati-Lafarge M, Boudjemaa A, et al
    Computational Fluid Dynamics and Genotyping to explore Airborne Transmission of Respiratory Viruses in Hospitals.
    Int J Infect Dis. 2026 Apr 9:108697. doi: 10.1016/j.ijid.2026.108697.
    PubMed         Abstract available

  10. GARDINER LE, Lozano-Rojas D, Smith N, Espley J, et al
    Investigating prognostic classifications of pre-existing multiple long-term conditions for health outcomes one-year after COVID-19 hospitalisation: a UK prospective observational study.
    Int J Infect Dis. 2026 Apr 9:108695. doi: 10.1016/j.ijid.2026.108695.
    PubMed         Abstract available


    Intensive Care Med

  11. MYATRA SN, Nasa P, Chanchalani GP, Zimmerman JL, et al
    Gender equality and equity in intensive care: an international Delphi consensus study.
    Intensive Care Med. 2026 Apr 15. doi: 10.1007/s00134-026-08394.
    PubMed         Abstract available


    J Med Virol

  12. MULLER V, Kolditz M, Shvachko V, Oppelt T, et al
    Effectiveness of Remdesivir on All-Cause In-Hospital Mortality in Patients With Chronic Respiratory Comorbidities Who Are Hospitalized With COVID-19 in the United States.
    J Med Virol. 2026;98:e70926.
    PubMed         Abstract available

  13. CAPPARELLI E, Maggiolini D, Paschale M, Pavia C, et al
    Changes in ANA Positivity Following SARS-CoV-2 Outbreak in Lombardy Region, Italy.
    J Med Virol. 2026;98:e70927.
    PubMed         Abstract available


    J Virol

  14. RAHEJA H, Sahu R, Ghosh T, Paul S, et al
    HuR enhances SARS-CoV-2 non-structural protein translation through the genomic 5'-UTR, by promoting polypyrimidine tract-binding protein binding.
    J Virol. 2026 Apr 16:e0027626. doi: 10.1128/jvi.00276.
    PubMed         Abstract available


    JAMA

  15. RUBIN R
    What to Know About Cicada, or BA.3.2, the Latest SARS-CoV-2 Variant Under Monitoring.
    JAMA. 2026 Apr 17. doi: 10.1001/jama.2026.5535.
    PubMed        


    Life Sci

  16. BARTOLOMEO CS, Lemes RMR, Morais RL, Pereria GC, et al
    Corrigendum to "SARS-CoV-2 infection and replication kinetics in different human cell types: The role of autophagy, cellular metabolism and ACE2 expression" [Life Sciences 308 (2022) 120930].
    Life Sci. 2026 Apr 9:124367. doi: 10.1016/j.lfs.2026.124367.
    PubMed        


    Nat Ment Health

  17. HIDALGO-PADILLA L, Gogarty E, Sarkodie R, Gaughran F, et al
    Primary care consultation modality and acute mental health service use in adults.
    Nat Ment Health. 2026;4:574-581.
    PubMed         Abstract available


    Nature

  18. STEINER C
    Almost half of traded wildlife carries disease-causing pathogens.
    Nature. 2026 Apr 9. doi: 10.1038/d41586-026-01121.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 19 '26)

 


    Biochem Biophys Res Commun

  1. CHEN M, Chen W, Jiang X, Liang S, et al
    Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline.
    Biochem Biophys Res Commun. 2026;814:153643.
    PubMed         Abstract available


    BMJ

  2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
    Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
    BMJ. 2026;393:e087578.
    PubMed         Abstract available


    Drug Saf

  3. HWANG CS, Lu Z, Russo M, Zakoul H, et al
    Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic.
    Drug Saf. 2026;49:519-528.
    PubMed         Abstract available

  4. COATES MM, Rowe SL, Sullivan SG, Munoz FM, et al
    Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID-19 Vaccination During Pregnancy.
    Drug Saf. 2026;49:567-580.
    PubMed         Abstract available

  5. RACHWAL O, Gutierrez-Lobon M, Cueto NS, Ventura AN, et al
    Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases.
    Drug Saf. 2026;49:581-590.
    PubMed         Abstract available

  6. JAJOU R, van Puijenbroek E, Overbeek J, Hek K, et al
    GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.
    Drug Saf. 2026;49:529-539.
    PubMed         Abstract available


    Epidemiol Infect

  7. GONZALES BE, Ochoa TJ, van der Sande MAB
    Inequalities in complete pneumococcal vaccination among Peruvian children before and after the COVID-19 pandemic: An evaluation using demographic and health surveys from 2018 to 2023.
    Epidemiol Infect. 2026;154:e49.
    PubMed         Abstract available

  8. KIMURA M, Asai Y, Tsuzuki S, Shimizu Y, et al
    Effectiveness of voluntary PCR testing against COVID-19 spread in remote Japanese islands.
    Epidemiol Infect. 2026;154:e48.
    PubMed         Abstract available


    J Virol Methods

  9. ASGHARI M, Golalipour M, Memarian A, Farazmandfar T, et al
    Presentation of multiple copies of a non-dominant surface epitope by circular RNA effectively induce an immune response against SARS-CoV-2.
    J Virol Methods. 2026;343:115378.
    PubMed         Abstract available

  10. CHIBA S
    Therapeutic mechanisms of early oseltamivir administration in the management of mild COVID-19 through the sympathetic nervous system: A scoping review.
    J Virol Methods. 2026;343:115386.
    PubMed         Abstract available


    Lancet

  11. JOHANSEN ND, Seco JP, Martinon-Torres F, Biering-Sorensen T, et al
    Unclear benefits of higher doses of influenza vaccine - Authors' reply.
    Lancet. 2026;407:1426.
    PubMed        

  12. FLAHAULT A
    Unclear benefits of higher doses of influenza vaccine.
    Lancet. 2026;407:1425-1426.
    PubMed        


    PLoS Biol

  13. SOLA I, Zuniga S
    New transcription signals in SARS-CoV-2 reshape virus-host interactions.
    PLoS Biol. 2026;24:e3003744.
    PubMed         Abstract available


    PLoS Comput Biol

  14. JEONG YD, Hart WS, Ishikane M, Kim KS, et al
    Identifying the optimal rapid antigen test for screening and determining the end of isolation: A modeling study.
    PLoS Comput Biol. 2026;22:e1013102.
    PubMed         Abstract available

  15. ANOKYE F, Li MWZ, Walker S, Hurford A, et al
    Quantifying SARS-CoV-2 Omicron variant spread and the impact of non-pharmaceutical interventions in Newfoundland and Labrador, Canada.
    PLoS Comput Biol. 2026;22:e1013562.
    PubMed         Abstract available


    PLoS One

  16. ABDELGHANY M, Yu F, Rennard S, Gwon Y, et al
    Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease.
    PLoS One. 2026;21:e0346878.
    PubMed         Abstract available

  17. BERBER E, Hanley HB, Gamez BM, Ross TM, et al
    Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022-2023, 2023-2024, and 2024-2025 seasons.
    PLoS One. 2026;21:e0347314.
    PubMed         Abstract available

  18. MURALIDHAR K, Ngaybe MGB, Pope B, Nanjaiah S, et al
    Behavioural and Social Drivers (BeSD) of COVID-19 vaccination for children: A cross-sectional study of parental vaccine confidence and intent in Mysore, India.
    PLoS One. 2026;21:e0316877.
    PubMed         Abstract available

  19. BHUPATHI M, Hegde S, Molloy JC, Devarapu GCR, et al
    MobileLAMP: A low-cost, portable incubation device for isothermal nucleic acid amplification.
    PLoS One. 2026;21:e0346874.
    PubMed         Abstract available

  20. SHIMAZU Y, Isoda N, Hiono T, Hew YL, et al
    Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model.
    PLoS One. 2026;21:e0347205.
    PubMed         Abstract available

  21. GANGAT R, Ngah V, Tawonga R, Blanford JI, et al
    Spatial and temporal patterns of SARS-CoV-2 infection in uMgungundlovu, KwaZulu-Natal, South Africa.
    PLoS One. 2026;21:e0317648.
    PubMed         Abstract available

  22. VAN DUINKERKEN A, van der Velden PG, Duckers MLA, Baliatsas C, et al
    Revisiting the exposure criterion for PTSD: Using the COVID-19 pandemic as an opportunity to assess measurement invariance of PTSD symptoms across event types.
    PLoS One. 2026;21:e0347315.
    PubMed         Abstract available

  23. KITTUR ME, Jones BDM, Imran S, Wang W, et al
    Impact of the COVID-19 pandemic on adults accessing specialist psychiatric care: A cross-sectional Canadian analysis.
    PLoS One. 2026;21:e0346913.
    PubMed         Abstract available

  24. CASJENS S, Hovanec J, Glaser N, Massag J, et al
    Occupational risk factors for depression and anxiety symptoms: Insights from a large cohort study during and after the SARS-CoV-2 pandemic.
    PLoS One. 2026;21:e0346871.
    PubMed         Abstract available

  25. JIANG KP, Bennett S, Yager P
    Heat-actuated valve implementation in a point-of-care, paper-based microfluidic device for infectious disease detection.
    PLoS One. 2026;21:e0344750.
    PubMed         Abstract available

  26. ABBAS U, Laghari RN, Ahmed I, Musawwir UA, et al
    Acute SARS-CoV-2 viral load and systemic inflammation are associated with neuropsychiatric and musculoskeletal symptoms in long COVID.
    PLoS One. 2026;21:e0346978.
    PubMed         Abstract available

  27. OZATO N, Hori S, Miyai N, Takase H, et al
    Association of visceral fat and plasmacytoid dendritic cell-derived interferon alpha with SARS-CoV-2 infection.
    PLoS One. 2026;21:e0344870.
    PubMed         Abstract available

  28. DIAS GF, Fan C, Han M, Wang X, et al
    COVID-19 in hemodialysis patients: New insights into metabolomic profile dynamics from 60 days pre- to 60 days post-diagnosis.
    PLoS One. 2026;21:e0346687.
    PubMed         Abstract available

  29. MOHTASHAM F, Hashemi Nazari SS, Pourhoseingholi MA, Kavousi K, et al
    Hybrid feature-selection and diversity-guided stacking framework for interpretable ensemble learning: Application to COVID-19 mortality prediction.
    PLoS One. 2026;21:e0341198.
    PubMed         Abstract available

  30. LEE SJ, Kim J, Han M, Lee JA, et al
    Distinct plasma cytokine and chemokine profiles in severe COVID-19 and septic shock.
    PLoS One. 2026;21:e0347126.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  31. GOLDMAN N, Pebley AR
    The Latino health experience: Past and future.
    Proc Natl Acad Sci U S A. 2026;123:e2530795123.
    PubMed         Abstract available

  32. HUOT M, Wang D, Shakhnovich E, Monasson R, et al
    Constrained evolutionary funnels shape viral immune escape.
    Proc Natl Acad Sci U S A. 2026;123:e2536956123.
    PubMed         Abstract available

  33. FARIAS A, Bridgeman VL, Rodrigues FS, Puttur F, et al
    Type I interferons induced upon respiratory viral infection impair lung metastatic initiation.
    Proc Natl Acad Sci U S A. 2026;123:e2412919123.
    PubMed         Abstract available


    Vaccine

  34. HSIEH SM, Choi MJ, Chen YC, Cheng SY, et al
    Cost-effectiveness of vaccination of older adults with an MF59(R)-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan.
    Vaccine. 2026;80:128533.
    PubMed         Abstract available

  35. ANYALECHI EG, Marquez PL, Rubin MN, Johannsen SP, et al
    Safety of seasonal inactivated influenza vaccines in children 6 months-17 years of age in the Vaccine Adverse Events Reporting System (VAERS) 2018-2023: before, during, and after the COVID-19 pandemic public health emergency.
    Vaccine. 2026;81:128569.
    PubMed         Abstract available


    Virology

  36. SWIERKOT J, Tyczynska KM, Siemaszko J, Madej M, et al
    The association of selected genetic polymorphisms with adverse events following COVID-19 vaccination: a single-centre prospective observational cohort study.
    Virology. 2026;619:110876.
    PubMed         Abstract available

  37. CHEN G, Liang D, Liu M, Lv Z, et al
    Theaflavins suppresses RSV infection by modulating the MAVS-I-IFN pathway.
    Virology. 2026;619:110872.
    PubMed         Abstract available

  38. LIU R, Patterson L, Yeasmin M, Kim KH, et al
    Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.
    Virology. 2026;619:110884.
    PubMed         Abstract available

  39. WANG Z, Wongnak R, Oba M, Mizutani T, et al
    Omicron RBD expressed in E. coli outperforms mammalian-expressed S1 spike protein in generating highly neutralizing anti-SARS-CoV-2 antibodies in mice.
    Virology. 2026;619:110894.
    PubMed         Abstract available

  40. RICHARDSON SAS, Boodhoo N, Bhat S, Wells J, et al
    Differential outcomes of viral co-infections with high pathogenicity avian influenza A(H5N6) and SARS-CoV-2 in mammalian in vitro systems.
    Virology. 2026;620:110912.
    PubMed         Abstract available

#Ocular findings in Northern #Gannets following an #outbreak of high pathogenicity avian #influenza #H5N1

 


Abstract

During 2021-2022, high pathogenicity avian influenza (HPAI) caused mass mortality in wild birds across Europe, with Northern Gannets (Morus bassanus) among the most affected. Following the outbreak, unusual alterations in the species' characteristic pale iris were observed in some individuals. Opportunistically captured gannets on Bass Rock (n=52), selected to represent a range of iris pigmentation, were examined. Slit-lamp biomicroscopy, indirect ophthalmoscopy, rebound tonometry and photography were performed. Iris pigmentation was classified as normal, mottled or black. Eleven birds underwent avian influenza virus (AIV) serology. Histopathology was performed on two eyes. Abnormal iris pigmentation was found in 74% of adult and immature gannets, with 61% affected bilaterally. Additional signs consistent with uveitis were present in 77% of affected birds. Iris pigmentation abnormalities were positively associated with AIV H5 seropositivity (Fishers exact test, P=0.018). Histopathology from affected eyes showed increased melanin deposition and disorganisation, including loss of a distinct anterior layer of melanocytic cells and hypertrophy of melanocytes within the iris stroma. Field conditions limited uniform lighting and concurrent serology. Iris pigmentation changes were associated with prior HPAI exposure and frequently accompanied by signs of uveitis, suggesting iris alterations may indicate past infection and potential chronic sequelae.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.04.15.718625v1

____

Frequent seasonal #reassortment between high and low path #viruses drives the diversification of #influenza #H5N1

 


Abstract

Since 2021, highly pathogenic (HPAI) H5N1 viruses have spread across the Americas, diversifying via reassortment into new genotypes that have spilled into humans and livestock, raising fears of a new influenza pandemic. Pandemic lineages are typically associated with reassortment, but we currently have limited understanding of where and when reassortment is expected to occur, which limits our ability to assess pandemic risks. Using a dataset of 9,052 full-genome sequences, we show that reassortment and novel genotype formation are associated with seasonal variation in low pathogenicity avian influenza (LPAI) cases and with the spatial and host distributions of viral transmission. We pinpoint ducks, geese, and the Central flyway as frequent sources of new genotypes, and show that reassortment rates vary seasonally, driven by mixing between high- and low-pathogenicity viruses. Cattle spillover genotypes (B3.13 and D1.1) evolved during periods of high reassortment, implicating reassortment as a common occurrence in lineages evolving during particular time periods. Together, these findings reframe reassortment as a predictable ecological process, with direct implications for how surveillance and pandemic risk assessment should be designed.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

US Centers for Disease Control Insight Net, CDC-RFA-FT-23-0069

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.04.17.719307v1

____

Saturday, April 18, 2026

History of Mass Transportation: The Skoda 242260-8 Electric locomotive class 242

 


By Rainerhaufe - http://de.wikipedia.org/wiki/Bild:242.jpg, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=4340624

Source: 


Link: https://en.wikipedia.org/wiki/%C4%8CD_Class_242

____

#Taiwan #CDC issued a #statement regarding journal research on transmission of viruses from farmed #shrimp in #China to #humans (Apr. 18 '26)

 


Recently, online discussions have focused on a study published in the international journal *Nature Microbiology*, which suggests that *Cryptant Dead Noda Virus* (CMNV), found in aquatic animals, may have the potential to spread across species to humans, potentially causing persistent high-tension viral anterior uveitis (POH-VAU). 

The Centers for Disease Control (CDC) stated that currently only China has reported suspected human cases of CMNV, distributed across 18 provinces with high aquaculture activity

Major international public health organizations such as the WHO, the US CDC, and the European Centre for Disease Prevention and Control (ECDC) have not reported any CMNV-related cases or listed it as an urgent threat. 

The CDC assesses the risk of domestic transmission as extremely low and will continue monitoring with agricultural authorities.

The CDC further explained that the study infers that human infection with CMNV may be related to handling or consuming raw seafood; however, further evidence is needed to confirm whether this virus has the ability to effectively infect human eye tissue. 

The Taiwan Centers for Disease Control (CDC) emphasizes that there have been no large-scale human outbreaks or community transmission events caused by CMNV globally at present, and there is no evidence of infection through the general consumption of cooked seafood

The CDC will continue to monitor relevant international outbreaks, develop human specimen testing technologies and methods, and establish relevant sampling and testing conditions for risk monitoring and early warning.

According to the monitoring of the Animal and Plant Health Inspection and Quarantine Bureau of the Ministry of Agriculture, there have never been any CMNV outbreaks in shrimp farms in Taiwan. 

The CDC's overall assessment is that the risk of domestic transmission is extremely low, but both agriculture and health authorities will continue to strengthen monitoring. 

CMNV has been listed as an emerging infectious disease by the World Organisation for Animal Health, and infection cases have been reported in shrimp farms in China and Thailand

The CDC urges travelers to China and Thailand to take special precautions against CMNV, including thoroughly cooking seafood, avoiding raw seafood for high-risk groups (such as those with chronic diseases), wearing gloves when handling raw seafood, avoiding direct contact with raw food if hands are open, and washing hands thoroughly with soap and water after handling to reduce the risk of infection by various pathogens.

Source: 


Link: https://www.cdc.gov.tw/Bulletin/Detail/JAKoFRedyjAVo_zmdBsCfQ?typeid=9

____

Friday, April 17, 2026

#USA, #Wastewater Data for Avian #Influenza #H5 (#CDC, April 17 '26)

 


{Excerpt}

(...)

Time Period: April 05, 2026 - April 11, 2026

-- A(H5) Detection6 site(s) (1.3%)

-- No Detection454 site(s) (98.7%)

-- No samples103 site(s)




(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html

____

#UK, #England: #Antibiotics and MenB #vaccination to be offered to young people in #Dorset following 3 cases of invasive #meningococcal disease (UKHSA, Apr. 17 '26)

 


The UK Health Security Agency (UKHSA) is working with Dorset Council, the NHS and local partners following 3 confirmed cases of meningococcal infection (meningitis) in young people in Weymouth, Dorset.

The cases were confirmed between 20 March and 15 April. All have received treatment and are recovering well. Close contacts of the cases have already been offered antibiotics as a precaution.

Two of the cases attend Budmouth Academy and the other attends Wey Valley Academy. Further information about the signs and symptoms of meningitis has been shared with students and parents of both schools.

Around 300 to 400 cases of meningococcal disease are diagnosed in England every year. These 3 cases have been confirmed as Meningitis B (MenB) and are the same sub-strain type, but a different sub-strain to the one detected recently in Kent.

The 2 cases who attend Budmouth Academy are contacts of each other, but currently no confirmed epidemiological link has been made between these cases and the third individual who attends Wey Valley Academy. This may mean that this strain of MenB bacteria is transmitting more widely among young people in Weymouth. Due to this, and as an additional precautionary measure, antibiotics and MenB vaccination will now be offered to young people currently in school years 7 to 13 (or equivalent), or anyone not in full time education who would be in one of these year groups, who study in or live in the Weymouth, Portland and Chickerell areas of Dorset.

Dr Beth Smout, UKHSA Deputy Director said:

''We are working closely with partners to follow up and offer precautionary antibiotics to close contacts of the cases. However, meningococcal disease does not spread easily, and outbreaks like we have seen recently in Kent are rare. These cases are not linked to the Kent outbreak and it is important to be aware that this outbreak is not on the same scale as we saw in Kent in terms of speed of transmission or severity.

''However, it is possible that we will see further cases linked to these latest cases in Weymouth and we understand that there will be concern among students, staff, parents and the local community as we widen our offer of antibiotics and vaccination. I’d like to stress that this is an additional precaution, and that we’re following national guidelines to reduce the risk of the infection spreading. School pupils and staff should attend school as normal if they remain well.

UKHSA is now recommending a single dose of antibiotics and a meningitis B vaccine be offered to young people who live or go to school in the Weymouth area, as follows:

-- anyone who is a resident in Weymouth or Portland or Chickerell and is in current school years 7 to 13 (or equivalent), or anyone not in full time education who would be in one of these year groups

-- anyone who attends an educational setting in the Weymouth, Portland or Chickerell area and is in current school years 7 to 13 (or equivalent).

This will be offered in stages starting with Budmouth Academy and Wey Valley schools, as the cases attend these settings. Pupils that attend other schools and other eligible children in Weymouth who do not attend school will be invited after the weekend.

Young people under 16 should be accompanied by a parent or guardian who is able to provide consent at the time.

More information on the vaccination schedule will be provided in due course.

Dr Smout added:

''Meningococcal disease can progress rapidly, so it’s essential that everyone is alert to the signs and symptoms of meningococcal meningitis and septicaemia, which can include a fever, headache, rapid breathing, drowsiness, shivering, vomiting and cold hands and feet. Septicaemia can also cause a characteristic rash that does not fade when pressed against a glass. If the disease is suspected, you should seek immediate medical attention as the disease can progress rapidly.

''It’s also important for teenagers to ensure they take up the MenACWY vaccine routinely offered by the NHS – but also to be aware that this vaccine does not protect against Men B, which is why knowing the symptoms and seeking early treatment is so important.

Young people in school years 7 to 13 in Weymouth are strongly encouraged to take up the offer of antibiotics and MenB vaccination and we are grateful to all those involved in our investigations so far for assisting us.

UKHSA and Dorset Council have issued advice to staff, parents and carers at all educational settings in the area.

Anyone who becomes unwell with symptoms of meningitis and septicaemia should seek medical help urgently at the closest Accident and Emergency Department or by dialling 999. Early treatment can be lifesaving. If you’re not sure if your symptoms are serious, use NHS 111 online or call 111 for further advice.

Source: 


Link: https://www.gov.uk/government/news/antibiotics-and-menb-vaccination-to-be-offered-to-young-people-in-dorset

____

#Poland - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 


A poultry farm in the Lubelskie Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7451

____

#India - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 


A poultry farm in the Chhattisgarh Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7453

____

#Russia - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification [FINAL]

Wild Anatidae (unidentified) in the Yevrey Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7426

____

#Chile - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 


A poultry farm in AraucanĂ­a Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7456

____

#Sweden - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


-- In accordance with the WOAH Terrestrial Animal Health Code, Article 10.4.1, point 4, this outbreak does not change the disease-free status of Sweden as these are wild birds or birds kept in a single household, and therefore do not fall within the WOAH definition of poultry.

__

-- Tjörn

- A Whooper swan was found dead. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

-- Varberg

- A Eurasian Buzzard was found dead. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

- A Peregrin falcon was found dead. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

-- Nyköping

- An Eurasian buzzard was found dead. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

-- Södertälje

- A Eurasian jackdaw was found dead. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

-- Hallstahammar

- A Eurasian jackdaw was found dead. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

-- Växjö

- A Canada goose and a Greylag goose were found dead and sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

Source: 


Link: https://wahis.woah.org/#/in-review/7452

____

#Infection of the #bovine mammary #gland by avian #H5N1 subclade 2.3.4.4b #influenza viruses

 


Abstract

The emergence of the panzootic clade of highly pathogenic avian influenza H5N1 (2.3.4.4b) in 2020 marked a major expansion in the host range of influenza A viruses (IAVs), raising concerns about further cross‑species transmission events and zoonotic spillover. Introduction of 2.3.4.4b viruses into U.S. dairy herds has resulted in widespread circulation, accompanied by reduced milk yield, mastitis, and high viral loads in milk. Notably, virus circulation in dairy cattle represents a novel route for mammalian adaptation and transmission that has already led to more than 40 human cases in the U.S. since 2024. Here, we investigated whether avian clade 2.3.4.4b viruses could infect mammary tissue from Aberdeen Angus, Holstein Friesian, and Limousin cattle, three breeds commonly farmed in Europe, the Americas, and Oceania. Using mammary gland explants, we inoculated tissues with attenuated reassortant viruses expressing the haemagglutinin and neuraminidase glycoproteins of three 2.3.4.4b viruses that predated the emergence of H5N1 in US cattle: A/chicken/England/053052/2021 (AIV07), A/chicken/Scotland/054477/2021 (AIV09), and A/chicken/England/085598/2022 (AIV48). Infected epithelial cells were identified using immunohistochemistry in explants from both the teat and gland cistern for all three breeds following infection with AIV09 and AIV48, indicating that mammary tissue from each of the three tested cattle breeds cattle is permissive to H5N1 infection. Lectin staining showed expression of both α2,3‑linked and α2,6‑linked sialic acids in the mammary tissue of all donors showing that all three breeds have the potential to support infection with both avian-adapted and mammalian adapted IAVs. Together, these findings demonstrate that mammary glands from both beef and dairy cattle breeds are permissive to infection with avian‑adapted and mammalian-adapted H5N1 viruses and highlight the potential for this tissue to act as a mixing vessel for IAV reassortment, underscoring the need to include cattle in ongoing H5N1 surveillance and risk‑assessment frameworks.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Medical Research Council, https://ror.org/03x94j517, MR/Y03368X/1, MR/Y03368X/1, MC_UU_0034/2, MC_UU_0034/3, MC_UU_0034/1

Biotechnology and Biological Sciences Research Council, https://ror.org/00cwqg982, BB/V004697/1

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.04.16.718897v1

____

Acquisition of specific #human respiratory tract binding of 2.3.4.4b #H5N1 #hemagglutinins requires multiple #mutations

 


Abstract

It has been suggested that the hemagglutinin of the human-infecting cattle-derived 2.3.4.4b virus A/Texas/34 (H5TX) requires only one mutation, namely Q226L, to switch from binding avian-type to human-type receptor preference. In this study, we examined the binding of H5TX Q226L, along with other key mutations, to sections of human trachea. We conclude that, while H5TX Q226L can bind human-type receptors, more than a single mutation is required for this protein to bind to human respiratory tract tissue. We also report changes in receptor-binding specificity of another 2.3.4.4b HA mutant, H5FR Q226L, associated with the presence of a multibasic cleavage site. This study offers insight into the determinants of evolution towards human-type receptor binding in currently circulating H5Nx viruses. It also emphasizes the importance of testing individual strains using additional methods, including tissue-based approaches, alongside synthetic glycans.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

NWO, OCENW.M20.106

Horizon, 862605

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.04.16.718875v1

____

My New Space

Most Popular Posts